Navigation Links
AbbVie's Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
Date:5/6/2013

NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA).

The designation is based, in part, on positive data from AbbVie's clinical development program, including the Phase 2b clinical trial M11-652, known as "Aviator." The Aviator study was conducted in 571 patients infected with HCV GT1.  Results from the treatment arms evaluating ABT-450/r + ABT-267 + ABT-333 with and without ribavirin demonstrated that the regimen provided high sustained viral response rates (SVR) with 12 weeks of therapy in patients who had not been previously treated (treatment naive) and in those who had failed prior therapy with pegylated interferon and ribavirin (null responders), regardless of sex, HCV subtype, stage of fibrosis, viral load or IL28B genotype.  

According to the FDA, Breakthrough Therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for Breakthrough Therapy designation includes preliminary clinical evidence demonstrating a drug may have substantial improvement on at least one clinically significant endpoint compared to available therapy. A Breakthrough Therapy designation conveys all of the fast track program features, as well as more intensive FDA guidance on an efficient drug development program.(1)

"AbbVie is pleased that the FDA has granted Breakthrough Therapy designation to our 3-DAA combination with and without ribavirin. We feel it reflects the potential of this regimen to be important in the treatment of HCV," said John M
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bayer Initiates Phase III Trial of Investigational Inhaled Amikacin Solution (BAY41-6551T) in Mechanically Ventilated Patients with Gram-negative Pneumonia
2. Bayers Investigational Riociguat Granted U.S. FDA Priority Review for Pulmonary Arterial Hypertension and Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
3. Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013
4. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
5. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
6. Genocea Publishes Preclinical Data For Investigational Vaccine Candidate For HSV-2
7. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
8. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
9. BHR Pharma Investigational Traumatic Brain Injury Treatment Receives European Medicines Agency Orphan Medicinal Product Designation
10. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
11. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... - New Solution That Makes ... JIN Co., Ltd. will launch JINS MEME "ACADEMIC PACK" ... yen or $5,000 (without tax /including two pairs of JINS ... a dedicated solution of "JINS MEME" to academic researchers, and ... generated by electrooculography and six-axis sensors without API. (*Physiological data ...
(Date:11/26/2014)... 2014  Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... On Tuesday, December 2, the company will ... Healthcare Conference.  D. Keith Grossman , President and ... company beginning at 11:30 a.m., Eastern Standard Time (8:30 ...
(Date:11/26/2014)... 2014   Royal Philips (NYSE: ... availability of its portfolio of diagnostic X-ray ... Opta[i] , ProGrade and PrimaryDiagnost[ii]. With new releases ... the U.S., and availability of all these solutions ... customers innovative solutions designed to meet the needs ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Thoratec Announces Presentations At Investor Conferences For December 2014 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
... in Management of Transplant Recipients with Cancer, ... in post-transplant patients with cancer is challenging.,Clinicians must ... while,simultaneously monitoring the impact of chemotherapeutic agents on ... management of such patients will be,presented today at ...
Cached Medicine Technology:Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6Penn State Hershey Transplant Program Uses Assay to Monitor Cell-Mediated Immunity 2
(Date:11/27/2014)... "As a nurse I see patients every ... incontinence," said an inventor from Whiting, N.J. "I put ... to prevent leakage and keep them dry and comfortable." ... This prevents stains on pants, skirts and bottoms, which ... that the individual has time to get to the ...
(Date:11/27/2014)... 27, 2014 Nearly 1,100 Risperdal ... in a consolidated litigation now underway in Pennsylvania ... Documents recently updated in the Philadelphia Court of ... state proceeding, all of which involve a drug ... psychiatric conditions. Many of the cases in this ...
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, 2014 ... a second language, new research suggests. But anyone who tries ... brain boost, the small study finds. The brain ... Ping Li, co-director of the Center for Brain, Behavior and ... Li said, that "the brain networks of the more successful ...
(Date:11/27/2014)... News) -- Most babies and young children don,t need ... and Drug Administration says. Over-the-counter (OTC) cold and ... than 2 because they could cause serious and potentially ... average about three colds a year, but children get ... might want to give them pain relievers, decongestants and ...
(Date:11/27/2014)... Thompson HealthDay Reporter WEDNESDAY, ... appears to be safe and produces an immune system response ... early clinical trial results reported by the U.S. National Institutes ... trial for the vaccine paves the way for field-testing it ... Leone as early as January, said Dr. Anthony Fauci, director ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... Roche Pharmaceuticals has granted a sub-license to Indian firm Hetero ... is the only drug known so far to have any ... virus. ,Hetero is based at Hyderabad and ... distributed across South East Asia and Africa. Commenting on the ...
... gearing up worldover, as the australian health minister ... be provided to all patients visiting queensland// hospital ... smoking following which the Australian Competition and Consumer ... sponsor anti-smoking advertising. ,Cigaretter manufacturers in ...
... and Resorts has banned smoking in the rooms, restaurants, bars ... Canada and the Caribbean from January 2006//., ,Guests will ... outdoor areas. , ,Westin said research among its customers ... room. , ,"Nobody likes to walk into a smoky ...
... has revealed that routine chest X-rays may serve to identify ... 172,000 Americans // are expected to be diagnosed with lung ... as this disease is invariably detected late. ,Earlier ... tumors, or patients were put through risky surgery as a ...
... and Finch showed the effect of childhood infections and ... diseases // . ,They collected mortality data ... and Switzerland from different years but ending with individuals ... was an important factor in treating childhood illness. ...
... Scientists in Scotland have discovered that an ordinary kitchen ... superbug, which is capable of resisting many // antibiotics. ... brand of the kitchen-scouring pad alone contains the cure ... according to reports can be grown on one particular ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: